Edward H. Romond

11.9k total citations · 3 hit papers
61 papers, 3.9k citations indexed

About

Edward H. Romond is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edward H. Romond has authored 61 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 24 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edward H. Romond's work include HER2/EGFR in Cancer Research (22 papers), Breast Cancer Treatment Studies (22 papers) and Advanced Breast Cancer Therapies (11 papers). Edward H. Romond is often cited by papers focused on HER2/EGFR in Cancer Research (22 papers), Breast Cancer Treatment Studies (22 papers) and Advanced Breast Cancer Therapies (11 papers). Edward H. Romond collaborates with scholars based in United States, Austria and Italy. Edward H. Romond's co-authors include Norman Wolmark, Charles E. Geyer, Jong‐Hyeon Jeong, Nancy E. Davidson, Silvana Martino, Vera J. Suman, Eleftherios P. Mamounas, Priya Rastogi, Sandra M. Swain and Elizabeth Tan-Chiu and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Edward H. Romond

58 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

2014 671 citations Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology profile →
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

2005 568 citations Elizabeth Tan-Chiu, Greg Yothers et al. Journal of Clinical Oncology profile →
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

2011 539 citations Edward H. Romond, Jong‐Hyeon Jeong et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Edward H. Romond

Since Specialization

Citations

This map shows the geographic impact of Edward H. Romond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward H. Romond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward H. Romond more than expected).

Fields of papers citing papers by Edward H. Romond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward H. Romond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward H. Romond. The network helps show where Edward H. Romond may publish in the future.

Co-authorship network of co-authors of Edward H. Romond

This figure shows the co-authorship network connecting the top 25 collaborators of Edward H. Romond. A scholar is included among the top collaborators of Edward H. Romond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward H. Romond. Edward H. Romond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Influence of depression on breast cancer treatment and survival: A Kentucky population‐based study 2023 ·Cancer ·Feitong Lei, Robin C. Vanderpool, Laurie E. McLouth, Edward H. Romond, Quan Chen, Eric B. Durbin, T. C. Tucker, Eric Tai, Bin Huang	15
2	Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution 2019 ·Clinical Breast Cancer ·(unknown), Kurt Hodges, Rachel L. Stewart, Jianrong Wu, Bin Huang, Kathleen L. O’Connor, Edward H. Romond	9
3	Systemic therapy for HER2-positive early-stage breast cancer 2016 ·Current Problems in Cancer ·Aju Mathew, Edward H. Romond	7
4	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 2015 ·Cancer Epidemiology Biomarkers & Prevention ·Reena S. Cecchini, Sandra M. Swain, Joseph P. Costantino, Priya Rastogi, Jong‐Hyeon Jeong, Stewart Anderson, Gong Tang, Charles E. Geyer, Barry C. Lembersky, Edward H. Romond, Alexander Paterson, Norman Wolmark	33
5	Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy 2015 ·JNCI Journal of the National Cancer Institute ·Ismail Jatoi, Hanna Bandos, Jong‐Hyeon Jeong, William F. Anderson, Edward H. Romond, Eleftherios P. Mamounas, Norman Wolmark	17
6	Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer 2014 ·Clinical Breast Cancer ·Amy Chen, Li Chen, (unknown), Edward H. Romond, (unknown), (unknown), Suleiman Massarweh	11
7	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial 2013 ·Blood ·Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar, Edward H. Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, T. T. Yee, Robert Klamroth, Wing-Yen Wong, (unknown), Werner Engl, Peter L. Turecek, (unknown), Bruce M. Ewenstein	87
8	A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure 2013 ·Breast Cancer Research and Treatment ·Suleiman Massarweh, Edward H. Romond, Esther P. Black, (unknown), Brent J. Shelton, (unknown), (unknown), Richard Elledge	48
9	A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation 2012 ·Breast Cancer Research and Treatment ·Li Chen, Edward H. Romond, Saurin Chokshi, Hayder Saeed, (unknown), (unknown), (unknown), Heidi L. Weiss, Suleiman Massarweh	13
10	Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas? 2010 ·Pathology Research International ·(unknown), Michael L. Cibull, Terry D. Stratton, Luis Samayoa, Edward H. Romond, Patrick C. McGrath, Rouzan G. Karabakhtsian	5
11	Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer 2010 ·Clinical Breast Cancer ·(unknown), Edward H. Romond	5
12	Distinct lymph nodal sonographic characteristics in breast cancer patients at high risk for axillary metastases correlate with the final axillary stage 2008 ·British Journal of Radiology ·Alison Moore, (unknown), (unknown), (unknown), Patrick C. McGrath, H. P. Wright, Karen Weisinger, Edward H. Romond, Luis Samayoa	49
13	The Critical Role of Axillary Ultrasound and Aspiration Biopsy in the Management of Breast Cancer Patients with Clinically Negative Axilla 2007 ·Annals of Surgical Oncology ·(unknown), Patrick C. McGrath, (unknown), Joseph T. Davis, (unknown), (unknown), M L Cibull, (unknown), Edward H. Romond, Karen Weisinger, Luis Samayoa	34
14	Size of Sentinel Node Tumor Deposits and Extent of Axillary Lymph Node Involvement: Which Breast Cancer Patients May Benefit From Less Aggressive Axillary Dissections? 2007 ·Annals of Surgical Oncology ·(unknown), Joseph T. Davis, (unknown), (unknown), Michael L. Cibull, Patrick C. McGrath, Edward H. Romond, Angela R. Moore, Luis Samayoa	7
15	Advances in adjuvant therapy for breast cancer. 2006 ·PubMed ·Dennis J. Slamon, Edward H. Romond, Edith A. Perez	29
16	Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 breakdown → 2005 ·Journal of Clinical Oncology ·Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond, Charles E. Geyer, Michael S. Ewer, Deborah Keefe, Richard P. Shannon, Sandra M. Swain, Ann Brown, Louis Fehrenbacher, Victor G. Vogel, Thomas E. Seay, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark, John Bryant	568
17	Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience 2002 ·JNCI Journal of the National Cancer Institute ·Soonmyung Paik, Jennifer Bryant, Elizabeth Tan-Chiu, Edward H. Romond, W. Douglas B. Hiller, K Park, A Brown, Greg Yothers, Stewart Anderson, Roger P. Smith, D. Lawrence Wickerham, Norman Wolmark	375
18	COMBINED IN VITRO AND IN VIVO T LYMPHOCYTE DEPLETION FOR THE CONTROL OF GRAFT-VERSUS-HOST DISEASE FOLLOWING HAPLOIDENTICAL MARROW TRANSPLANT 1996 ·Transplantation ·P. Jean Henslee‐Downey, Rudolph S. Parrish, John S. Macdonald, Edward H. Romond, (unknown), Charles W. Coffey, (unknown), John Thompson	42
19	Lymphocyte Infusion for Delayed Extramedullary Relapse of Acute Leukemia Following Bone Marrow Transplantation 1996 ·Leukemia & lymphoma ·Donald R. Fleming, Martha F. Greenwood, Juanita Garrison, John D. Geil, Edward H. Romond	15
20	Bone Marrow Transplantation 1989 ·Hospital Practice ·Edward H. Romond, John S. Macdonald, Catherine Martin, (unknown), (unknown), John F. Kilner, Joseph Engelberg, (unknown)	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact